RECRUITING

Affect-based Impulsivity in Borderline Personality Disorder

Conditions

Borderline Personality Disorder (BPD)Healthy Controls Group - Age and Sex-matched

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to investigate how personality traits and neuroendocrine systems relate to decision-making patterns in individuals 18-45 years old. The main question it aims to answer is how neuroendocrine activity impacts decision-making. Participants will complete online behavioral tasks, a stress induction procedure, self-report surveys, and a cognitive assessment. During the session, psychophysiological measures will be collected, including electrocardiogram (ECG) and cardiac impedance (ICG) to monitor heart rate and blood flow, as well as electrodermal activity (EDA), blood drop samples, and saliva collection to assess nervous system activity.

Official Title

Affect-based Impulsivity in Borderline Personality Disorder: Developing a Neurocomputational Phenotype

Quick Facts

Study Start:2025-05-10

Study Completion:2026-04-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06880640

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* Score of 38 or higher on Personality Assessment Inventory-Borderline Scale (PAI-BOR) * Participants in the BPD group will be primarily recruited from the two 1. 3+ BPD symptoms, one of which must be affective instability, per clinical interview 2. Participants must score at least 80 on the Reynolds Intellectual Screening Test (RIST). * Score of 12 or lower on PAI-BOR * Score below 50th percentile on World Health Organization Disability Assessment Schedule (WHODAS) * Absence of any current or lifetime psychiatric disorder, including personality disorders as determined by diagnostic interviews (SIDP and SCID), if the participant had participated in the lab's other studies (IRB Nos. 20-1735 and 21-0602).	* Use of as needed antihypertensive agents within 12 hours prior to lab visit * Inability to refrain from using as needed psychotropic medications for 12 hours prior to lab visit * History of psychotic disorder, Bipolar I disorder, autism spectrum disorder, reactive attachment disorder, pervasive developmental disorder, motor disorder, head injury, mental retardation, neurological disorder, or current substance dependence * Family history of Bipolar I disorder in a first degree relative. * Participants are also excluded for any of the following: cardiac pacemaker, aneurysm clip, cochlear implants, pregnancy, shrapnel, history of metal fragments in eyes, neurostimulators, weight of 250 lbs. or more, or claustrophobia.

Inclusion Criteria

Exclusion Criteria

* Score of 38 or higher on Personality Assessment Inventory-Borderline Scale (PAI-BOR)
* Participants in the BPD group will be primarily recruited from the two
1. 3+ BPD symptoms, one of which must be affective instability, per clinical interview
2. Participants must score at least 80 on the Reynolds Intellectual Screening Test (RIST).
* Score of 12 or lower on PAI-BOR
* Score below 50th percentile on World Health Organization Disability Assessment Schedule (WHODAS)
* Absence of any current or lifetime psychiatric disorder, including personality disorders as determined by diagnostic interviews (SIDP and SCID), if the participant had participated in the lab's other studies (IRB Nos. 20-1735 and 21-0602).

* Use of as needed antihypertensive agents within 12 hours prior to lab visit
* Inability to refrain from using as needed psychotropic medications for 12 hours prior to lab visit
* History of psychotic disorder, Bipolar I disorder, autism spectrum disorder, reactive attachment disorder, pervasive developmental disorder, motor disorder, head injury, mental retardation, neurological disorder, or current substance dependence
* Family history of Bipolar I disorder in a first degree relative.
* Participants are also excluded for any of the following: cardiac pacemaker, aneurysm clip, cochlear implants, pregnancy, shrapnel, history of metal fragments in eyes, neurostimulators, weight of 250 lbs. or more, or claustrophobia.

Contacts and Locations

Study Contact

Michael N Hallquist, PhD

CONTACT

412-613-9306

michael.hallquist@unc.edu

Principal Investigator

Michael Hallquist, PhD

PRINCIPAL_INVESTIGATOR

University of North Carolina, Chapel Hill

Study Locations (Sites)

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27514

United States

Collaborators and Investigators

Sponsor: University of North Carolina, Chapel Hill

Michael Hallquist, PhD, PRINCIPAL_INVESTIGATOR, University of North Carolina, Chapel Hill

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-10

Study Completion Date2026-04-01

Study Record Updates

Study Start Date2025-05-10

Study Completion Date2026-04-01

Terms related to this study

Additional Relevant MeSH Terms

Borderline Personality Disorder (BPD)
Healthy Controls Group - Age and Sex-matched